Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Dyne Therapeutics announces Chief Scientific Officer transition » 16:09
06/02/21
06/02
16:09
06/02/21
16:09
DYN

Dyne Therapeutics

$18.96 /

+0.41 (+2.21%)

Dyne Therapeutics…

Dyne Therapeutics announced that Romesh Subramanian, Ph.D. has chosen to step down as Chief Scientific Officer for personal reasons and will continue to serve as an advisor to Dyne. Concurrently, Oxana Beskrovnaya, Ph.D., who has served as Dyne's senior VP, head of research since January 2020, has been appointed Chief Scientific Officer.

ShowHide Related Items >><<
DYN Dyne Therapeutics
$18.96 /

+0.41 (+2.21%)

DYN Dyne Therapeutics
$18.96 /

+0.41 (+2.21%)

03/05/21 Stifel
Dyne Therapeutics weakness a buying opportunity, says Stifel
02/09/21
Dyne Therapeutics initiated with a Buy at JonesTrading
01/07/21 Piper Sandler
Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper
10/12/20 Jefferies
Dyne Therapeutics initiated with a Buy at Jefferies
DYN Dyne Therapeutics
$18.96 /

+0.41 (+2.21%)

  • 21
    Jan
  • 17
    Sep
DYN Dyne Therapeutics
$18.96 /

+0.41 (+2.21%)

DYN Dyne Therapeutics
$18.96 /

+0.41 (+2.21%)

Over a month ago
Conference/Events
Dyne Therapeutics to hold a conference call » 15:45
05/14/21
05/14
15:45
05/14/21
15:45
DYN

Dyne Therapeutics

$17.60 /

+0.59 (+3.47%)

Management reviews the…

Management reviews the company's DM1 program, pre-clinical data and an overview of the presentation at the ASGCT 24th Annual Meeting on a conference call to be held on May 14 at 4 pm. Webcast Link

ShowHide Related Items >><<
DYN Dyne Therapeutics
$17.60 /

+0.59 (+3.47%)

DYN Dyne Therapeutics
$17.60 /

+0.59 (+3.47%)

03/05/21 Stifel
Dyne Therapeutics weakness a buying opportunity, says Stifel
02/09/21
Dyne Therapeutics initiated with a Buy at JonesTrading
01/07/21 Piper Sandler
Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper
10/12/20 Jefferies
Dyne Therapeutics initiated with a Buy at Jefferies
DYN Dyne Therapeutics
$17.60 /

+0.59 (+3.47%)

  • 21
    Jan
  • 17
    Sep
DYN Dyne Therapeutics
$17.60 /

+0.59 (+3.47%)

DYN Dyne Therapeutics
$17.60 /

+0.59 (+3.47%)

Conference/Events
Dyne Therapeutics to hold a conference call » 08:54
05/14/21
05/14
08:54
05/14/21
08:54
DYN

Dyne Therapeutics

$17.01 /

-0.26 (-1.51%)

Management reviews the…

Management reviews the company's DM1 program, pre-clinical data and an overview of the presentation at the ASGCT 24th Annual Meeting on a conference call to be held on May 14 at 4 pm. Webcast Link

ShowHide Related Items >><<
DYN Dyne Therapeutics
$17.01 /

-0.26 (-1.51%)

DYN Dyne Therapeutics
$17.01 /

-0.26 (-1.51%)

03/05/21 Stifel
Dyne Therapeutics weakness a buying opportunity, says Stifel
02/09/21
Dyne Therapeutics initiated with a Buy at JonesTrading
01/07/21 Piper Sandler
Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper
10/12/20 Jefferies
Dyne Therapeutics initiated with a Buy at Jefferies
DYN Dyne Therapeutics
$17.01 /

-0.26 (-1.51%)

  • 21
    Jan
  • 17
    Sep
DYN Dyne Therapeutics
$17.01 /

-0.26 (-1.51%)

DYN Dyne Therapeutics
$17.01 /

-0.26 (-1.51%)

Hot Stocks
Dyne Therapeutics present preclinical data on myotonic dystrophy type 1 program » 07:18
05/14/21
05/14
07:18
05/14/21
07:18
DYN

Dyne Therapeutics

$17.01 /

-0.26 (-1.51%)

Dyne Therapeutics is…

Dyne Therapeutics is presenting new preclinical data from its myotonic dystrophy type 1 program during the American Society of Gene & Cell Therapy 24th Annual Meeting, including results demonstrating sustained knockdown of toxic human nuclear DMPK RNA, the genetic basis of the disease. Dyne's DM1 candidate consists of an antigen-binding fragment antibody conjugated to an antisense oligonucleotide to enable targeted muscle tissue delivery to reduce accumulation of toxic DMPK RNA in the nucleus, release splicing proteins, allow normal mRNA processing and translation of normal proteins, and potentially stop or reverse the disease. To assess the ability of its DM1 candidate to reduce toxic human nuclear DMPK RNA, Dyne developed a hTfR1/DMSXL mouse model that expresses the human TfR1 and carries a human DMPK gene that represents a severe DM1 phenotype with more than 1,000 CTG repeats. In January 2021, Dyne reported data showing that two doses of its DM1 candidate resulted in significant toxic human nuclear DMPK knockdown at 14 days. New data being presented at ASGCT are consistent with these findings, with the candidate demonstrating an approximately 40% reduction in DMPK heart foci at 14 days. Dyne expanded its analysis in the hTfR1/DMSXL model to evaluate the administration of a single, low 10 mg/kg dose of its lead DM1 candidate after 4 weeks. These new data show sustained DMPK knockdown at 4 weeks: 51% in the diaphragm, 46% in both the heart and tibialis anterior, and 42% in the gastrocnemius. Dyne's candidate was well tolerated in the hTfR1/DMSXL studies. Additionally, Dyne is reporting during ASGCT new in vitro findings from DM1 patient cells with approximately 380 and 2,600 CTG repeats, where its candidate showed a robust, dose-dependent reduction in DMPK RNA, nuclear foci and correction of splicing defects as measured by BIN1 exon 11 inclusion. The results in the cell line with approximately 2,600 CTG repeats are particularly notable given the severity of DM1 disease represented.

ShowHide Related Items >><<
DYN Dyne Therapeutics
$17.01 /

-0.26 (-1.51%)

DYN Dyne Therapeutics
$17.01 /

-0.26 (-1.51%)

03/05/21 Stifel
Dyne Therapeutics weakness a buying opportunity, says Stifel
02/09/21
Dyne Therapeutics initiated with a Buy at JonesTrading
01/07/21 Piper Sandler
Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper
10/12/20 Jefferies
Dyne Therapeutics initiated with a Buy at Jefferies
DYN Dyne Therapeutics
$17.01 /

-0.26 (-1.51%)

  • 21
    Jan
  • 17
    Sep
DYN Dyne Therapeutics
$17.01 /

-0.26 (-1.51%)

DYN Dyne Therapeutics
$17.01 /

-0.26 (-1.51%)

Earnings
Dyne Therapeutics reports Q1 EPS (50c), consensus (60) » 07:45
05/06/21
05/06
07:45
05/06/21
07:45
DYN

Dyne Therapeutics

$17.79 /

+0.29 (+1.66%)

"We continued to…

"We continued to make significant progress to start 2021, including generating new preclinical data in our DM1 program that will be featured during the upcoming ASGCT Annual Meeting, further strengthening our leadership team with key appointments and enhancing our financial foundation with cash runway expected into the second half of 2024," said Joshua Brumm, president and chief executive officer of Dyne. "We are focused on executing across all aspects of the business as we drive our three programs to the clinic, advance our efforts to deliver life-transforming therapies to patients and pursue our goal of building the world's leading muscle disease company."

ShowHide Related Items >><<
DYN Dyne Therapeutics
$17.79 /

+0.29 (+1.66%)

DYN Dyne Therapeutics
$17.79 /

+0.29 (+1.66%)

03/05/21 Stifel
Dyne Therapeutics weakness a buying opportunity, says Stifel
02/09/21
Dyne Therapeutics initiated with a Buy at JonesTrading
01/07/21 Piper Sandler
Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper
10/12/20 Jefferies
Dyne Therapeutics initiated with a Buy at Jefferies
DYN Dyne Therapeutics
$17.79 /

+0.29 (+1.66%)

  • 21
    Jan
  • 17
    Sep
DYN Dyne Therapeutics
$17.79 /

+0.29 (+1.66%)

DYN Dyne Therapeutics
$17.79 /

+0.29 (+1.66%)

Options
Eight new option listings and two option delistings on March 26th » 08:30
03/26/21
03/26
08:30
03/26/21
08:30
CAP

Capitol Investment Corp. V

$9.85 /

-0.025 (-0.25%)

, DYN

Dyne Therapeutics

$14.62 /

+0.6 (+4.28%)

, EYES

Second Sight

$8.93 /

+0.09 (+1.02%)

, HAYW

Hayward

$16.00 /

-0.615 (-3.70%)

, NSTB

Northern Star Investment Corp. II

$9.91 /

-0.03 (-0.30%)

, SANA

Sana Biotechnology

$30.44 /

-1.36 (-4.28%)

, GEN

Genesis Healthcare

/

+

, GSUM

Gridsum

$1.94 /

-0.005 (-0.26%)

New option listings for…

New option listings for March 26th include Breeze Holdings Acquisition Corporation (BREZ), Capitol Investment Corp V (Class A Stock) (CAP), Dyne Therapeutics Inc (DYN), Second Sight (EYES), Genesis Healthcare Inc (Class A Stock) (GENN), Hayward Holdings Inc (HAYW), Northern Star Investment Corp II (Class A Stock) (NSTB), and Sana Biotechnology Inc (SANA). Option delistings effective March 26th include Genesis Healthcare Inc (Class A Stock) (GEN) and Gridsum Holdings Inc (ADS) (GSUM).

ShowHide Related Items >><<
SANA Sana Biotechnology
$30.44 /

-1.36 (-4.28%)

NSTB Northern Star Investment Corp. II
$9.91 /

-0.03 (-0.30%)

GSUM Gridsum
$1.94 /

-0.005 (-0.26%)

GEN Genesis Healthcare
/

+

EYES Second Sight
$8.93 /

+0.09 (+1.02%)

DYN Dyne Therapeutics
$14.62 /

+0.6 (+4.28%)

CAP Capitol Investment Corp. V
$9.85 /

-0.025 (-0.25%)

DYN Dyne Therapeutics
$14.62 /

+0.6 (+4.28%)

03/05/21 Stifel
Dyne Therapeutics weakness a buying opportunity, says Stifel
02/09/21
Dyne Therapeutics initiated with a Buy at JonesTrading
01/07/21 Piper Sandler
Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper
10/12/20 Jefferies
Dyne Therapeutics initiated with a Buy at Jefferies
EYES Second Sight
$8.93 /

+0.09 (+1.02%)

04/01/20 H.C. Wainwright
Second Sight rating placed under review at H.C. Wainwright
HAYW Hayward
$16.00 /

-0.615 (-3.70%)

NSTB Northern Star Investment Corp. II
$9.91 /

-0.03 (-0.30%)

SANA Sana Biotechnology
$30.44 /

-1.36 (-4.28%)

03/01/21 Morgan Stanley
Sana Biotechnology initiated with an Overweight at Morgan Stanley
03/01/21 JPMorgan
Sana Biotechnology initiated with a Neutral at JPMorgan
03/01/21 BofA
Sana Biotechnology initiated with a Buy at BofA
03/01/21 Goldman Sachs
Sana Biotechnology initiated with a Neutral at Goldman Sachs
GEN Genesis Healthcare
/

+

01/25/21 Credit Suisse
Genesis Healthcare downgraded to Underperform from Neutral at Credit Suisse
08/11/20 Credit Suisse
Healthcare Services downgraded to Neutral from Outperform at Credit Suisse
GSUM Gridsum
$1.94 /

-0.005 (-0.26%)

DYN Dyne Therapeutics
$14.62 /

+0.6 (+4.28%)

  • 12
    Mar
  • 04
    Feb
  • 21
    Jan
  • 17
    Sep
  • 01
    May
SANA Sana Biotechnology
$30.44 /

-1.36 (-4.28%)

HAYW Hayward
$16.00 /

-0.615 (-3.70%)

EYES Second Sight
$8.93 /

+0.09 (+1.02%)

DYN Dyne Therapeutics
$14.62 /

+0.6 (+4.28%)

CAP Capitol Investment Corp. V
$9.85 /

-0.025 (-0.25%)

Over a quarter ago
Conference/Events
Muscular Dystrophy Association to hold a virtual conference » 04:55
03/18/21
03/18
04:55
03/18/21
04:55
ALXN

Alexion

$153.23 /

-0.09 (-0.06%)

, BHVN

Biohaven Pharmaceutical

$77.11 /

+1.39 (+1.84%)

, BIIB

Biogen

$264.14 /

+4.36 (+1.68%)

, CPRX

Catalyst Pharmaceuticals

$4.22 /

+0.1 (+2.43%)

, CYTK

Cytokinetics

$25.69 /

+1.87 (+7.85%)

, DYN

Dyne Therapeutics

$16.58 /

-0.055 (-0.33%)

, FOLD

Amicus

$10.55 /

+0.06 (+0.57%)

, NVS

Novartis

$85.74 /

-0.23 (-0.27%)

, ORPH

Orphazyme

$12.75 /

-0.55 (-4.14%)

, PKI

PerkinElmer

$126.38 /

+0.4 (+0.32%)

, PTCT

PTC Therapeutics

$55.75 /

-1.98 (-3.43%)

, REGN

Regeneron

$496.30 /

+14.06 (+2.92%)

, SLDB

Solid Biosciences

$6.67 /

+0.22 (+3.41%)

, SNY

Sanofi

$49.06 /

-0.33 (-0.67%)

, SRPT

Sarepta

$84.92 /

+0.505 (+0.60%)

MDA Clinical &…

MDA Clinical & Scientific Virtual Conference 2021 will be held on March 14-18. Webcast Link

ShowHide Related Items >><<
SRPT Sarepta
$84.92 /

+0.505 (+0.60%)

SNY Sanofi
$49.06 /

-0.33 (-0.67%)

SLDB Solid Biosciences
$6.67 /

+0.22 (+3.41%)

REGN Regeneron
$496.30 /

+14.06 (+2.92%)

PTCT PTC Therapeutics
$55.75 /

-1.98 (-3.43%)

PKI PerkinElmer
$126.38 /

+0.4 (+0.32%)

ORPH Orphazyme
$12.75 /

-0.55 (-4.14%)

NVS Novartis
$85.74 /

-0.23 (-0.27%)

FOLD Amicus
$10.55 /

+0.06 (+0.57%)

DYN Dyne Therapeutics
$16.58 /

-0.055 (-0.33%)

CYTK Cytokinetics
$25.69 /

+1.87 (+7.85%)

CPRX Catalyst Pharmaceuticals
$4.22 /

+0.1 (+2.43%)

BIIB Biogen
$264.14 /

+4.36 (+1.68%)

BHVN Biohaven Pharmaceutical
$77.11 /

+1.39 (+1.84%)

ALXN Alexion
$153.23 /

-0.09 (-0.06%)

ALXN Alexion
$153.23 /

-0.09 (-0.06%)

02/04/21 Piper Sandler
Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler
02/04/21 Piper Sandler
Alexion downgraded to Neutral from Overweight at Piper Sandler
01/08/21 Raymond James
Alexion downgraded to Market Perform from Outperform at Raymond James
12/16/20 Truist
Alexion downgraded to Hold from Buy at Truist
BHVN Biohaven Pharmaceutical
$77.11 /

+1.39 (+1.84%)

03/11/21
Fly Intel: Top five analyst initiations
03/11/21 UBS
Biohaven Pharmaceutical initiated with a Buy at UBS
03/02/21 Mizuho
Biohaven Pharmaceutical price target raised to $103 from $93 at Mizuho
03/01/21 Piper Sandler
Biohaven price target raised to $110 from $90 at Piper Sandler
BIIB Biogen
$264.14 /

+4.36 (+1.68%)

02/17/21 Cantor Fitzgerald
Biogen price target lowered to $268 from $278 at Cantor Fitzgerald
02/08/21 Citi
Expert sees Biogen aducanumab approval 50/50 at best, says Citi
02/04/21 SVB Leerink
Biogen price target lowered to $380 from $430 at SVB Leerink
02/04/21 Credit Suisse
Biogen price target lowered to $338 from $350 at Credit Suisse
CPRX Catalyst Pharmaceuticals
$4.22 /

+0.1 (+2.43%)

03/16/21 Piper Sandler
Catalyst business continues to generate cash flow, says Piper Sandler
01/07/21 Piper Sandler
Piper says Catalyst's Firdapse commercial business performing as expected
01/06/21 Piper Sandler
Catalyst Firdapse commercial business performing as expected, says Piper Sandler
11/10/20 Piper Sandler
Catalyst Pharmaceuticals price target lowered to $5.50 from $6 at Piper Sandler
CYTK Cytokinetics
$25.69 /

+1.87 (+7.85%)

03/11/21 Wolfe Research
Cytokinetics initiated with an Outperform at Wolfe Research
02/18/21 Barclays
Cytokinetics initiated with an Overweight at Barclays
01/20/21 H.C. Wainwright
Cytokinetics price target raised to $41 from $22 at H.C. Wainwright
12/28/20 Oppenheimer
Amgen price target lowered to $266 from $274 at Oppenheimer
DYN Dyne Therapeutics
$16.58 /

-0.055 (-0.33%)

03/05/21 Stifel
Dyne Therapeutics weakness a buying opportunity, says Stifel
02/09/21
Dyne Therapeutics initiated with a Buy at JonesTrading
01/07/21 Piper Sandler
Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper
10/12/20 Jefferies
Dyne Therapeutics initiated with a Buy at Jefferies
FOLD Amicus
$10.55 /

+0.06 (+0.57%)

03/01/21 Stifel
Amicus initiated with a Hold at Stifel
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 JPMorgan
Amicus downgraded to Neutral on Pompe disease miss at JPMorgan
02/12/21 SVB Leerink
Amicus downgraded to Market Perform from Outperform at SVB Leerink
NVS Novartis
$85.74 /

-0.23 (-0.27%)

03/10/21
Fly Intel: Top five analyst downgrades
03/10/21 Argus
Novartis cut to Hold at Argus on slowing top-line growth, greater competition
03/10/21 Argus
Novartis downgraded to Hold from Buy at Argus
03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
ORPH Orphazyme
$12.75 /

-0.55 (-4.14%)

10/26/20 Guggenheim
Orphazyme initiated with a Buy at Guggenheim
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
PKI PerkinElmer
$126.38 /

+0.4 (+0.32%)

02/03/21 Citi
PerkinElmer price target raised to $155 from $150 at Citi
01/07/21 Piper Sandler
Oxford Immunotec downgraded to Neutral from Overweight at Piper Sandler
01/07/21 Wells Fargo
PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo
01/07/21 Wells Fargo
PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo
PTCT PTC Therapeutics
$55.75 /

-1.98 (-3.43%)

02/26/21 Cantor Fitzgerald
PTC Therapeutics price target lowered to $75 from $81 at Cantor Fitzgerald
02/12/21 BofA
PTC Therapeutics downgraded to Neutral from Buy at BofA
02/12/21 BofA
PTC Therapeutics downgraded to Neutral from Buy at BofA
01/05/21 Citi
PTC Therapeutics upgraded to Buy from Neutral at Citi
REGN Regeneron
$496.30 /

+14.06 (+2.92%)

03/11/21 Evercore ISI
Kodiak Sciences initiated with an Outperform at Evercore ISI
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
02/23/21 Credit Suisse
Regeneron price target raised to $760 from $753 at Credit Suisse
02/16/21 Cantor Fitzgerald
Regeneron price target lowered to $656 from $696 at Cantor Fitzgerald
SLDB Solid Biosciences
$6.67 /

+0.22 (+3.41%)

03/16/21 Chardan
Solid Biosciences price target raised to $20 from $12.50 at Chardan
03/16/21
Fly Intel: Top five analyst upgrades
03/16/21 SVB Leerink
Solid Biosciences upgraded to Outperform at SVB Leerink
03/16/21 SVB Leerink
Solid Biosciences upgraded to Outperform from Market Perform at SVB Leerink
SNY Sanofi
$49.06 /

-0.33 (-0.67%)

02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
01/19/21 UBS
Sanofi price target lowered to EUR 99 from EUR 100 at UBS
SRPT Sarepta
$84.92 /

+0.505 (+0.60%)

03/02/21 RBC Capital
Sarepta price target lowered to $132 from $143 at RBC Capital
03/02/21 Piper Sandler
Sarepta price target lowered to $130 from $140 at Piper Sandler
02/26/21 Mizuho
Sarepta price target raised to $160 from $158 at Mizuho
02/25/21 Piper Sandler
Piper says Sarepta's Amondys 45 approval comes with 'relatively clean label'
SRPT Sarepta
$84.92 /

+0.505 (+0.60%)

SNY Sanofi
$49.06 /

-0.33 (-0.67%)

SLDB Solid Biosciences
$6.67 /

+0.22 (+3.41%)

REGN Regeneron
$496.30 /

+14.06 (+2.92%)

PTCT PTC Therapeutics
$55.75 /

-1.98 (-3.43%)

PKI PerkinElmer
$126.38 /

+0.4 (+0.32%)

NVS Novartis
$85.74 /

-0.23 (-0.27%)

FOLD Amicus
$10.55 /

+0.06 (+0.57%)

DYN Dyne Therapeutics
$16.58 /

-0.055 (-0.33%)

CYTK Cytokinetics
$25.69 /

+1.87 (+7.85%)

CPRX Catalyst Pharmaceuticals
$4.22 /

+0.1 (+2.43%)

BIIB Biogen
$264.14 /

+4.36 (+1.68%)

BHVN Biohaven Pharmaceutical
$77.11 /

+1.39 (+1.84%)

ALXN Alexion
$153.23 /

-0.09 (-0.06%)

  • 19
    Mar
  • 16
    Mar
  • 21
    Jan
  • 29
    Sep
  • 17
    Sep
  • 17
    Jul
  • 27
    May
SNY Sanofi
$49.06 /

-0.33 (-0.67%)

REGN Regeneron
$496.30 /

+14.06 (+2.92%)

NVS Novartis
$85.74 /

-0.23 (-0.27%)

FOLD Amicus
$10.55 /

+0.06 (+0.57%)

BIIB Biogen
$264.14 /

+4.36 (+1.68%)

ALXN Alexion
$153.23 /

-0.09 (-0.06%)

SRPT Sarepta
$84.92 /

+0.505 (+0.60%)

SNY Sanofi
$49.06 /

-0.33 (-0.67%)

SLDB Solid Biosciences
$6.67 /

+0.22 (+3.41%)

REGN Regeneron
$496.30 /

+14.06 (+2.92%)

PTCT PTC Therapeutics
$55.75 /

-1.98 (-3.43%)

PKI PerkinElmer
$126.38 /

+0.4 (+0.32%)

ORPH Orphazyme
$12.75 /

-0.55 (-4.14%)

NVS Novartis
$85.74 /

-0.23 (-0.27%)

FOLD Amicus
$10.55 /

+0.06 (+0.57%)

DYN Dyne Therapeutics
$16.58 /

-0.055 (-0.33%)

CYTK Cytokinetics
$25.69 /

+1.87 (+7.85%)

CPRX Catalyst Pharmaceuticals
$4.22 /

+0.1 (+2.43%)

BIIB Biogen
$264.14 /

+4.36 (+1.68%)

ALXN Alexion
$153.23 /

-0.09 (-0.06%)

REGN Regeneron
$496.30 /

+14.06 (+2.92%)

FOLD Amicus
$10.55 /

+0.06 (+0.57%)

CYTK Cytokinetics
$25.69 /

+1.87 (+7.85%)

BIIB Biogen
$264.14 /

+4.36 (+1.68%)

ALXN Alexion
$153.23 /

-0.09 (-0.06%)

Conference/Events
Muscular Dystrophy Association to hold a virtual conference » 04:55
03/18/21
03/18
04:55
03/18/21
04:55
ALXN

Alexion

$153.23 /

-0.09 (-0.06%)

, SDNA

Sedona Corporation

$0.00 /

+ (+0.00%)

, BIIB

Biogen

$264.14 /

+4.36 (+1.68%)

, PTCT

PTC Therapeutics

$55.75 /

-1.98 (-3.43%)

, SRPT

Sarepta

$84.92 /

+0.505 (+0.60%)

, NVS

Novartis

$85.74 /

-0.23 (-0.27%)

, SNY

Sanofi

$49.06 /

-0.33 (-0.67%)

, SLDB

Solid Biosciences

$6.67 /

+0.22 (+3.41%)

, REGN

Regeneron

$496.30 /

+14.06 (+2.92%)

, BHVN

Biohaven Pharmaceutical

$77.11 /

+1.39 (+1.84%)

, ORPH

Orphazyme

$12.75 /

-0.55 (-4.14%)

, CPRX

Catalyst Pharmaceuticals

$4.22 /

+0.1 (+2.43%)

, DYN

Dyne Therapeutics

$16.58 /

-0.055 (-0.33%)

, CYTK

Cytokinetics

$25.69 /

+1.87 (+7.85%)

, FOLD

Amicus

$10.55 /

+0.06 (+0.57%)

, PKI

PerkinElmer

$126.38 /

+0.4 (+0.32%)

MDA Clinical &…

MDA Clinical & Scientific Virtual Conference 2021 will be held on March 14-18. Webcast Link

ShowHide Related Items >><<
SRPT Sarepta
$84.92 /

+0.505 (+0.60%)

SNY Sanofi
$49.06 /

-0.33 (-0.67%)

SLDB Solid Biosciences
$6.67 /

+0.22 (+3.41%)

REGN Regeneron
$496.30 /

+14.06 (+2.92%)

PTCT PTC Therapeutics
$55.75 /

-1.98 (-3.43%)

PKI PerkinElmer
$126.38 /

+0.4 (+0.32%)

ORPH Orphazyme
$12.75 /

-0.55 (-4.14%)

NVS Novartis
$85.74 /

-0.23 (-0.27%)

FOLD Amicus
$10.55 /

+0.06 (+0.57%)

DYN Dyne Therapeutics
$16.58 /

-0.055 (-0.33%)

CYTK Cytokinetics
$25.69 /

+1.87 (+7.85%)

CPRX Catalyst Pharmaceuticals
$4.22 /

+0.1 (+2.43%)

BIIB Biogen
$264.14 /

+4.36 (+1.68%)

BHVN Biohaven Pharmaceutical
$77.11 /

+1.39 (+1.84%)

ALXN Alexion
$153.23 /

-0.09 (-0.06%)

ALXN Alexion
$153.23 /

-0.09 (-0.06%)

02/04/21 Piper Sandler
Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler
02/04/21 Piper Sandler
Alexion downgraded to Neutral from Overweight at Piper Sandler
01/08/21 Raymond James
Alexion downgraded to Market Perform from Outperform at Raymond James
12/16/20 Truist
Alexion downgraded to Hold from Buy at Truist
SDNA Sedona Corporation
$0.00 /

+ (+0.00%)

BIIB Biogen
$264.14 /

+4.36 (+1.68%)

02/17/21 Cantor Fitzgerald
Biogen price target lowered to $268 from $278 at Cantor Fitzgerald
02/08/21 Citi
Expert sees Biogen aducanumab approval 50/50 at best, says Citi
02/04/21 SVB Leerink
Biogen price target lowered to $380 from $430 at SVB Leerink
02/04/21 Credit Suisse
Biogen price target lowered to $338 from $350 at Credit Suisse
PTCT PTC Therapeutics
$55.75 /

-1.98 (-3.43%)

02/26/21 Cantor Fitzgerald
PTC Therapeutics price target lowered to $75 from $81 at Cantor Fitzgerald
02/12/21 BofA
PTC Therapeutics downgraded to Neutral from Buy at BofA
02/12/21 BofA
PTC Therapeutics downgraded to Neutral from Buy at BofA
01/05/21 Citi
PTC Therapeutics upgraded to Buy from Neutral at Citi
SRPT Sarepta
$84.92 /

+0.505 (+0.60%)

03/02/21 RBC Capital
Sarepta price target lowered to $132 from $143 at RBC Capital
03/02/21 Piper Sandler
Sarepta price target lowered to $130 from $140 at Piper Sandler
02/26/21 Mizuho
Sarepta price target raised to $160 from $158 at Mizuho
02/25/21 Piper Sandler
Piper says Sarepta's Amondys 45 approval comes with 'relatively clean label'
NVS Novartis
$85.74 /

-0.23 (-0.27%)

03/10/21
Fly Intel: Top five analyst downgrades
03/10/21 Argus
Novartis cut to Hold at Argus on slowing top-line growth, greater competition
03/10/21 Argus
Novartis downgraded to Hold from Buy at Argus
03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
SNY Sanofi
$49.06 /

-0.33 (-0.67%)

02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
01/19/21 UBS
Sanofi price target lowered to EUR 99 from EUR 100 at UBS
SLDB Solid Biosciences
$6.67 /

+0.22 (+3.41%)

03/16/21 Chardan
Solid Biosciences price target raised to $20 from $12.50 at Chardan
03/16/21
Fly Intel: Top five analyst upgrades
03/16/21 SVB Leerink
Solid Biosciences upgraded to Outperform at SVB Leerink
03/16/21 SVB Leerink
Solid Biosciences upgraded to Outperform from Market Perform at SVB Leerink
REGN Regeneron
$496.30 /

+14.06 (+2.92%)

03/11/21 Evercore ISI
Kodiak Sciences initiated with an Outperform at Evercore ISI
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
02/23/21 Credit Suisse
Regeneron price target raised to $760 from $753 at Credit Suisse
02/16/21 Cantor Fitzgerald
Regeneron price target lowered to $656 from $696 at Cantor Fitzgerald
BHVN Biohaven Pharmaceutical
$77.11 /

+1.39 (+1.84%)

03/11/21
Fly Intel: Top five analyst initiations
03/11/21 UBS
Biohaven Pharmaceutical initiated with a Buy at UBS
03/02/21 Mizuho
Biohaven Pharmaceutical price target raised to $103 from $93 at Mizuho
03/01/21 Piper Sandler
Biohaven price target raised to $110 from $90 at Piper Sandler
ORPH Orphazyme
$12.75 /

-0.55 (-4.14%)

10/26/20 Guggenheim
Orphazyme initiated with a Buy at Guggenheim
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
CPRX Catalyst Pharmaceuticals
$4.22 /

+0.1 (+2.43%)

03/16/21 Piper Sandler
Catalyst business continues to generate cash flow, says Piper Sandler
01/07/21 Piper Sandler
Piper says Catalyst's Firdapse commercial business performing as expected
01/06/21 Piper Sandler
Catalyst Firdapse commercial business performing as expected, says Piper Sandler
11/10/20 Piper Sandler
Catalyst Pharmaceuticals price target lowered to $5.50 from $6 at Piper Sandler
DYN Dyne Therapeutics
$16.58 /

-0.055 (-0.33%)

03/05/21 Stifel
Dyne Therapeutics weakness a buying opportunity, says Stifel
02/09/21
Dyne Therapeutics initiated with a Buy at JonesTrading
01/07/21 Piper Sandler
Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper
10/12/20 Jefferies
Dyne Therapeutics initiated with a Buy at Jefferies
CYTK Cytokinetics
$25.69 /

+1.87 (+7.85%)

03/11/21 Wolfe Research
Cytokinetics initiated with an Outperform at Wolfe Research
02/18/21 Barclays
Cytokinetics initiated with an Overweight at Barclays
01/20/21 H.C. Wainwright
Cytokinetics price target raised to $41 from $22 at H.C. Wainwright
12/28/20 Oppenheimer
Amgen price target lowered to $266 from $274 at Oppenheimer
FOLD Amicus
$10.55 /

+0.06 (+0.57%)

03/01/21 Stifel
Amicus initiated with a Hold at Stifel
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 JPMorgan
Amicus downgraded to Neutral on Pompe disease miss at JPMorgan
02/12/21 SVB Leerink
Amicus downgraded to Market Perform from Outperform at SVB Leerink
PKI PerkinElmer
$126.38 /

+0.4 (+0.32%)

02/03/21 Citi
PerkinElmer price target raised to $155 from $150 at Citi
01/07/21 Piper Sandler
Oxford Immunotec downgraded to Neutral from Overweight at Piper Sandler
01/07/21 Wells Fargo
PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo
01/07/21 Wells Fargo
PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo
SRPT Sarepta
$84.92 /

+0.505 (+0.60%)

SNY Sanofi
$49.06 /

-0.33 (-0.67%)

SLDB Solid Biosciences
$6.67 /

+0.22 (+3.41%)

REGN Regeneron
$496.30 /

+14.06 (+2.92%)

PTCT PTC Therapeutics
$55.75 /

-1.98 (-3.43%)

PKI PerkinElmer
$126.38 /

+0.4 (+0.32%)

NVS Novartis
$85.74 /

-0.23 (-0.27%)

FOLD Amicus
$10.55 /

+0.06 (+0.57%)

DYN Dyne Therapeutics
$16.58 /

-0.055 (-0.33%)

CYTK Cytokinetics
$25.69 /

+1.87 (+7.85%)

CPRX Catalyst Pharmaceuticals
$4.22 /

+0.1 (+2.43%)

BIIB Biogen
$264.14 /

+4.36 (+1.68%)

BHVN Biohaven Pharmaceutical
$77.11 /

+1.39 (+1.84%)

ALXN Alexion
$153.23 /

-0.09 (-0.06%)

  • 19
    Mar
  • 16
    Mar
  • 21
    Jan
  • 29
    Sep
  • 17
    Sep
  • 17
    Jul
  • 27
    May
SNY Sanofi
$49.06 /

-0.33 (-0.67%)

REGN Regeneron
$496.30 /

+14.06 (+2.92%)

NVS Novartis
$85.74 /

-0.23 (-0.27%)

FOLD Amicus
$10.55 /

+0.06 (+0.57%)

BIIB Biogen
$264.14 /

+4.36 (+1.68%)

ALXN Alexion
$153.23 /

-0.09 (-0.06%)

SRPT Sarepta
$84.92 /

+0.505 (+0.60%)

SNY Sanofi
$49.06 /

-0.33 (-0.67%)

SLDB Solid Biosciences
$6.67 /

+0.22 (+3.41%)

REGN Regeneron
$496.30 /

+14.06 (+2.92%)

PTCT PTC Therapeutics
$55.75 /

-1.98 (-3.43%)

PKI PerkinElmer
$126.38 /

+0.4 (+0.32%)

ORPH Orphazyme
$12.75 /

-0.55 (-4.14%)

NVS Novartis
$85.74 /

-0.23 (-0.27%)

FOLD Amicus
$10.55 /

+0.06 (+0.57%)

DYN Dyne Therapeutics
$16.58 /

-0.055 (-0.33%)

CYTK Cytokinetics
$25.69 /

+1.87 (+7.85%)

CPRX Catalyst Pharmaceuticals
$4.22 /

+0.1 (+2.43%)

BIIB Biogen
$264.14 /

+4.36 (+1.68%)

ALXN Alexion
$153.23 /

-0.09 (-0.06%)

REGN Regeneron
$496.30 /

+14.06 (+2.92%)

FOLD Amicus
$10.55 /

+0.06 (+0.57%)

CYTK Cytokinetics
$25.69 /

+1.87 (+7.85%)

BIIB Biogen
$264.14 /

+4.36 (+1.68%)

ALXN Alexion
$153.23 /

-0.09 (-0.06%)

Conference/Events
Muscular Dystrophy Association to hold a virtual conference » 04:55
03/17/21
03/17
04:55
03/17/21
04:55
ALXN

Alexion

$153.32 /

+1.14 (+0.75%)

, SDNA

Sedona Corporation

$0.00 /

+ (+0.00%)

, BIIB

Biogen

$259.78 /

-0.37 (-0.14%)

, PTCT

PTC Therapeutics

$57.73 /

-0.3 (-0.52%)

, SRPT

Sarepta

$84.40 /

-1.39 (-1.62%)

, NVS

Novartis

$85.96 /

+0.66 (+0.77%)

, SNY

Sanofi

$49.40 /

+0.59 (+1.21%)

, SLDB

Solid Biosciences

$6.45 /

-3.115 (-32.58%)

, REGN

Regeneron

$482.31 /

-1.17 (-0.24%)

, BHVN

Biohaven Pharmaceutical

$75.72 /

-5.655 (-6.95%)

, ORPH

Orphazyme

$13.30 /

+0.84 (+6.74%)

, CPRX

Catalyst Pharmaceuticals

$4.12 /

+0.19 (+4.83%)

, DYN

Dyne Therapeutics

$16.62 /

-0.12 (-0.72%)

, CYTK

Cytokinetics

$23.85 /

-0.42 (-1.73%)

, FOLD

Amicus

$10.49 /

-0.28 (-2.60%)

, PKI

PerkinElmer

$125.97 /

-0.715 (-0.56%)

MDA Clinical &…

MDA Clinical & Scientific Virtual Conference 2021 will be held on March 14-18. Webcast Link

ShowHide Related Items >><<
SRPT Sarepta
$84.40 /

-1.39 (-1.62%)

SNY Sanofi
$49.40 /

+0.59 (+1.21%)

SLDB Solid Biosciences
$6.45 /

-3.115 (-32.58%)

REGN Regeneron
$482.31 /

-1.17 (-0.24%)

PTCT PTC Therapeutics
$57.73 /

-0.3 (-0.52%)

PKI PerkinElmer
$125.97 /

-0.715 (-0.56%)

ORPH Orphazyme
$13.30 /

+0.84 (+6.74%)

NVS Novartis
$85.96 /

+0.66 (+0.77%)

FOLD Amicus
$10.49 /

-0.28 (-2.60%)

DYN Dyne Therapeutics
$16.62 /

-0.12 (-0.72%)

CYTK Cytokinetics
$23.85 /

-0.42 (-1.73%)

CPRX Catalyst Pharmaceuticals
$4.12 /

+0.19 (+4.83%)

BIIB Biogen
$259.78 /

-0.37 (-0.14%)

BHVN Biohaven Pharmaceutical
$75.72 /

-5.655 (-6.95%)

ALXN Alexion
$153.32 /

+1.14 (+0.75%)

ALXN Alexion
$153.32 /

+1.14 (+0.75%)

02/04/21 Piper Sandler
Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler
02/04/21 Piper Sandler
Alexion downgraded to Neutral from Overweight at Piper Sandler
01/08/21 Raymond James
Alexion downgraded to Market Perform from Outperform at Raymond James
12/16/20 Truist
Alexion downgraded to Hold from Buy at Truist
SDNA Sedona Corporation
$0.00 /

+ (+0.00%)

BIIB Biogen
$259.78 /

-0.37 (-0.14%)

02/17/21 Cantor Fitzgerald
Biogen price target lowered to $268 from $278 at Cantor Fitzgerald
02/08/21 Citi
Expert sees Biogen aducanumab approval 50/50 at best, says Citi
02/04/21 SVB Leerink
Biogen price target lowered to $380 from $430 at SVB Leerink
02/04/21 Credit Suisse
Biogen price target lowered to $338 from $350 at Credit Suisse
PTCT PTC Therapeutics
$57.73 /

-0.3 (-0.52%)

02/26/21 Cantor Fitzgerald
PTC Therapeutics price target lowered to $75 from $81 at Cantor Fitzgerald
02/12/21 BofA
PTC Therapeutics downgraded to Neutral from Buy at BofA
02/12/21 BofA
PTC Therapeutics downgraded to Neutral from Buy at BofA
01/05/21 Citi
PTC Therapeutics upgraded to Buy from Neutral at Citi
SRPT Sarepta
$84.40 /

-1.39 (-1.62%)

03/02/21 RBC Capital
Sarepta price target lowered to $132 from $143 at RBC Capital
03/02/21 Piper Sandler
Sarepta price target lowered to $130 from $140 at Piper Sandler
02/26/21 Mizuho
Sarepta price target raised to $160 from $158 at Mizuho
02/25/21 Piper Sandler
Piper says Sarepta's Amondys 45 approval comes with 'relatively clean label'
NVS Novartis
$85.96 /

+0.66 (+0.77%)

03/10/21
Fly Intel: Top five analyst downgrades
03/10/21 Argus
Novartis cut to Hold at Argus on slowing top-line growth, greater competition
03/10/21 Argus
Novartis downgraded to Hold from Buy at Argus
03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
SNY Sanofi
$49.40 /

+0.59 (+1.21%)

02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
01/19/21 UBS
Sanofi price target lowered to EUR 99 from EUR 100 at UBS
SLDB Solid Biosciences
$6.45 /

-3.115 (-32.58%)

03/16/21 Chardan
Solid Biosciences price target raised to $20 from $12.50 at Chardan
03/16/21
Fly Intel: Top five analyst upgrades
03/16/21 SVB Leerink
Solid Biosciences upgraded to Outperform at SVB Leerink
03/16/21 SVB Leerink
Solid Biosciences upgraded to Outperform from Market Perform at SVB Leerink
REGN Regeneron
$482.31 /

-1.17 (-0.24%)

03/11/21 Evercore ISI
Kodiak Sciences initiated with an Outperform at Evercore ISI
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
02/23/21 Credit Suisse
Regeneron price target raised to $760 from $753 at Credit Suisse
02/16/21 Cantor Fitzgerald
Regeneron price target lowered to $656 from $696 at Cantor Fitzgerald
BHVN Biohaven Pharmaceutical
$75.72 /

-5.655 (-6.95%)

03/11/21
Fly Intel: Top five analyst initiations
03/11/21 UBS
Biohaven Pharmaceutical initiated with a Buy at UBS
03/02/21 Mizuho
Biohaven Pharmaceutical price target raised to $103 from $93 at Mizuho
03/01/21 Piper Sandler
Biohaven price target raised to $110 from $90 at Piper Sandler
ORPH Orphazyme
$13.30 /

+0.84 (+6.74%)

10/26/20 Guggenheim
Orphazyme initiated with a Buy at Guggenheim
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
CPRX Catalyst Pharmaceuticals
$4.12 /

+0.19 (+4.83%)

03/16/21 Piper Sandler
Catalyst business continues to generate cash flow, says Piper Sandler
01/07/21 Piper Sandler
Piper says Catalyst's Firdapse commercial business performing as expected
01/06/21 Piper Sandler
Catalyst Firdapse commercial business performing as expected, says Piper Sandler
11/10/20 Piper Sandler
Catalyst Pharmaceuticals price target lowered to $5.50 from $6 at Piper Sandler
DYN Dyne Therapeutics
$16.62 /

-0.12 (-0.72%)

03/05/21 Stifel
Dyne Therapeutics weakness a buying opportunity, says Stifel
02/09/21
Dyne Therapeutics initiated with a Buy at JonesTrading
01/07/21 Piper Sandler
Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper
10/12/20 Jefferies
Dyne Therapeutics initiated with a Buy at Jefferies
CYTK Cytokinetics
$23.85 /

-0.42 (-1.73%)

03/11/21 Wolfe Research
Cytokinetics initiated with an Outperform at Wolfe Research
02/18/21 Barclays
Cytokinetics initiated with an Overweight at Barclays
01/20/21 H.C. Wainwright
Cytokinetics price target raised to $41 from $22 at H.C. Wainwright
12/28/20 Oppenheimer
Amgen price target lowered to $266 from $274 at Oppenheimer
FOLD Amicus
$10.49 /

-0.28 (-2.60%)

03/01/21 Stifel
Amicus initiated with a Hold at Stifel
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 JPMorgan
Amicus downgraded to Neutral on Pompe disease miss at JPMorgan
02/12/21 SVB Leerink
Amicus downgraded to Market Perform from Outperform at SVB Leerink
PKI PerkinElmer
$125.97 /

-0.715 (-0.56%)

02/03/21 Citi
PerkinElmer price target raised to $155 from $150 at Citi
01/07/21 Piper Sandler
Oxford Immunotec downgraded to Neutral from Overweight at Piper Sandler
01/07/21 Wells Fargo
PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo
01/07/21 Wells Fargo
PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo
SRPT Sarepta
$84.40 /

-1.39 (-1.62%)

SNY Sanofi
$49.40 /

+0.59 (+1.21%)

SLDB Solid Biosciences
$6.45 /

-3.115 (-32.58%)

REGN Regeneron
$482.31 /

-1.17 (-0.24%)

PTCT PTC Therapeutics
$57.73 /

-0.3 (-0.52%)

PKI PerkinElmer
$125.97 /

-0.715 (-0.56%)

NVS Novartis
$85.96 /

+0.66 (+0.77%)

FOLD Amicus
$10.49 /

-0.28 (-2.60%)

DYN Dyne Therapeutics
$16.62 /

-0.12 (-0.72%)

CYTK Cytokinetics
$23.85 /

-0.42 (-1.73%)

CPRX Catalyst Pharmaceuticals
$4.12 /

+0.19 (+4.83%)

BIIB Biogen
$259.78 /

-0.37 (-0.14%)

BHVN Biohaven Pharmaceutical
$75.72 /

-5.655 (-6.95%)

ALXN Alexion
$153.32 /

+1.14 (+0.75%)

  • 16
    Mar
  • 21
    Jan
  • 29
    Sep
  • 17
    Sep
  • 17
    Jul
  • 27
    May
SNY Sanofi
$49.40 /

+0.59 (+1.21%)

REGN Regeneron
$482.31 /

-1.17 (-0.24%)

NVS Novartis
$85.96 /

+0.66 (+0.77%)

FOLD Amicus
$10.49 /

-0.28 (-2.60%)

BIIB Biogen
$259.78 /

-0.37 (-0.14%)

ALXN Alexion
$153.32 /

+1.14 (+0.75%)

SRPT Sarepta
$84.40 /

-1.39 (-1.62%)

SNY Sanofi
$49.40 /

+0.59 (+1.21%)

SLDB Solid Biosciences
$6.45 /

-3.115 (-32.58%)

REGN Regeneron
$482.31 /

-1.17 (-0.24%)

PTCT PTC Therapeutics
$57.73 /

-0.3 (-0.52%)

PKI PerkinElmer
$125.97 /

-0.715 (-0.56%)

ORPH Orphazyme
$13.30 /

+0.84 (+6.74%)

NVS Novartis
$85.96 /

+0.66 (+0.77%)

FOLD Amicus
$10.49 /

-0.28 (-2.60%)

DYN Dyne Therapeutics
$16.62 /

-0.12 (-0.72%)

CYTK Cytokinetics
$23.85 /

-0.42 (-1.73%)

CPRX Catalyst Pharmaceuticals
$4.12 /

+0.19 (+4.83%)

BIIB Biogen
$259.78 /

-0.37 (-0.14%)

ALXN Alexion
$153.32 /

+1.14 (+0.75%)

REGN Regeneron
$482.31 /

-1.17 (-0.24%)

FOLD Amicus
$10.49 /

-0.28 (-2.60%)

CYTK Cytokinetics
$23.85 /

-0.42 (-1.73%)

BIIB Biogen
$259.78 /

-0.37 (-0.14%)

ALXN Alexion
$153.32 /

+1.14 (+0.75%)

Conference/Events
Muscular Dystrophy Association to hold a virtual conference » 04:55
03/17/21
03/17
04:55
03/17/21
04:55
ALXN

Alexion

$153.32 /

+1.14 (+0.75%)

, BHVN

Biohaven Pharmaceutical

$75.72 /

-5.655 (-6.95%)

, BIIB

Biogen

$259.78 /

-0.37 (-0.14%)

, CPRX

Catalyst Pharmaceuticals

$4.12 /

+0.19 (+4.83%)

, CYTK

Cytokinetics

$23.85 /

-0.42 (-1.73%)

, DYN

Dyne Therapeutics

$16.62 /

-0.12 (-0.72%)

, FOLD

Amicus

$10.49 /

-0.28 (-2.60%)

, NVS

Novartis

$85.96 /

+0.66 (+0.77%)

, ORPH

Orphazyme

$13.30 /

+0.84 (+6.74%)

, PKI

PerkinElmer

$125.97 /

-0.715 (-0.56%)

, PTCT

PTC Therapeutics

$57.73 /

-0.3 (-0.52%)

, REGN

Regeneron

$482.31 /

-1.17 (-0.24%)

, SLDB

Solid Biosciences

$6.45 /

-3.115 (-32.58%)

, SNY

Sanofi

$49.40 /

+0.59 (+1.21%)

, SRPT

Sarepta

$84.40 /

-1.39 (-1.62%)

MDA Clinical &…

MDA Clinical & Scientific Virtual Conference 2021 will be held on March 14-18. Webcast Link

ShowHide Related Items >><<
SRPT Sarepta
$84.40 /

-1.39 (-1.62%)

SNY Sanofi
$49.40 /

+0.59 (+1.21%)

SLDB Solid Biosciences
$6.45 /

-3.115 (-32.58%)

REGN Regeneron
$482.31 /

-1.17 (-0.24%)

PTCT PTC Therapeutics
$57.73 /

-0.3 (-0.52%)

PKI PerkinElmer
$125.97 /

-0.715 (-0.56%)

ORPH Orphazyme
$13.30 /

+0.84 (+6.74%)

NVS Novartis
$85.96 /

+0.66 (+0.77%)

FOLD Amicus
$10.49 /

-0.28 (-2.60%)

DYN Dyne Therapeutics
$16.62 /

-0.12 (-0.72%)

CYTK Cytokinetics
$23.85 /

-0.42 (-1.73%)

CPRX Catalyst Pharmaceuticals
$4.12 /

+0.19 (+4.83%)

BIIB Biogen
$259.78 /

-0.37 (-0.14%)

BHVN Biohaven Pharmaceutical
$75.72 /

-5.655 (-6.95%)

ALXN Alexion
$153.32 /

+1.14 (+0.75%)

ALXN Alexion
$153.32 /

+1.14 (+0.75%)

02/04/21 Piper Sandler
Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler
02/04/21 Piper Sandler
Alexion downgraded to Neutral from Overweight at Piper Sandler
01/08/21 Raymond James
Alexion downgraded to Market Perform from Outperform at Raymond James
12/16/20 Truist
Alexion downgraded to Hold from Buy at Truist
BHVN Biohaven Pharmaceutical
$75.72 /

-5.655 (-6.95%)

03/11/21
Fly Intel: Top five analyst initiations
03/11/21 UBS
Biohaven Pharmaceutical initiated with a Buy at UBS
03/02/21 Mizuho
Biohaven Pharmaceutical price target raised to $103 from $93 at Mizuho
03/01/21 Piper Sandler
Biohaven price target raised to $110 from $90 at Piper Sandler
BIIB Biogen
$259.78 /

-0.37 (-0.14%)

02/17/21 Cantor Fitzgerald
Biogen price target lowered to $268 from $278 at Cantor Fitzgerald
02/08/21 Citi
Expert sees Biogen aducanumab approval 50/50 at best, says Citi
02/04/21 SVB Leerink
Biogen price target lowered to $380 from $430 at SVB Leerink
02/04/21 Credit Suisse
Biogen price target lowered to $338 from $350 at Credit Suisse
CPRX Catalyst Pharmaceuticals
$4.12 /

+0.19 (+4.83%)

03/16/21 Piper Sandler
Catalyst business continues to generate cash flow, says Piper Sandler
01/07/21 Piper Sandler
Piper says Catalyst's Firdapse commercial business performing as expected
01/06/21 Piper Sandler
Catalyst Firdapse commercial business performing as expected, says Piper Sandler
11/10/20 Piper Sandler
Catalyst Pharmaceuticals price target lowered to $5.50 from $6 at Piper Sandler
CYTK Cytokinetics
$23.85 /

-0.42 (-1.73%)

03/11/21 Wolfe Research
Cytokinetics initiated with an Outperform at Wolfe Research
02/18/21 Barclays
Cytokinetics initiated with an Overweight at Barclays
01/20/21 H.C. Wainwright
Cytokinetics price target raised to $41 from $22 at H.C. Wainwright
12/28/20 Oppenheimer
Amgen price target lowered to $266 from $274 at Oppenheimer
DYN Dyne Therapeutics
$16.62 /

-0.12 (-0.72%)

03/05/21 Stifel
Dyne Therapeutics weakness a buying opportunity, says Stifel
02/09/21
Dyne Therapeutics initiated with a Buy at JonesTrading
01/07/21 Piper Sandler
Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper
10/12/20 Jefferies
Dyne Therapeutics initiated with a Buy at Jefferies
FOLD Amicus
$10.49 /

-0.28 (-2.60%)

03/01/21 Stifel
Amicus initiated with a Hold at Stifel
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 JPMorgan
Amicus downgraded to Neutral on Pompe disease miss at JPMorgan
02/12/21 SVB Leerink
Amicus downgraded to Market Perform from Outperform at SVB Leerink
NVS Novartis
$85.96 /

+0.66 (+0.77%)

03/10/21
Fly Intel: Top five analyst downgrades
03/10/21 Argus
Novartis cut to Hold at Argus on slowing top-line growth, greater competition
03/10/21 Argus
Novartis downgraded to Hold from Buy at Argus
03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
ORPH Orphazyme
$13.30 /

+0.84 (+6.74%)

10/26/20 Guggenheim
Orphazyme initiated with a Buy at Guggenheim
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
PKI PerkinElmer
$125.97 /

-0.715 (-0.56%)

02/03/21 Citi
PerkinElmer price target raised to $155 from $150 at Citi
01/07/21 Piper Sandler
Oxford Immunotec downgraded to Neutral from Overweight at Piper Sandler
01/07/21 Wells Fargo
PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo
01/07/21 Wells Fargo
PerkinElmer upgraded to Overweight from Equal Weight at Wells Fargo
PTCT PTC Therapeutics
$57.73 /

-0.3 (-0.52%)

02/26/21 Cantor Fitzgerald
PTC Therapeutics price target lowered to $75 from $81 at Cantor Fitzgerald
02/12/21 BofA
PTC Therapeutics downgraded to Neutral from Buy at BofA
02/12/21 BofA
PTC Therapeutics downgraded to Neutral from Buy at BofA
01/05/21 Citi
PTC Therapeutics upgraded to Buy from Neutral at Citi
REGN Regeneron
$482.31 /

-1.17 (-0.24%)

03/11/21 Evercore ISI
Kodiak Sciences initiated with an Outperform at Evercore ISI
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
02/23/21 Credit Suisse
Regeneron price target raised to $760 from $753 at Credit Suisse
02/16/21 Cantor Fitzgerald
Regeneron price target lowered to $656 from $696 at Cantor Fitzgerald
SLDB Solid Biosciences
$6.45 /

-3.115 (-32.58%)

03/16/21 Chardan
Solid Biosciences price target raised to $20 from $12.50 at Chardan
03/16/21
Fly Intel: Top five analyst upgrades
03/16/21 SVB Leerink
Solid Biosciences upgraded to Outperform at SVB Leerink
03/16/21 SVB Leerink
Solid Biosciences upgraded to Outperform from Market Perform at SVB Leerink
SNY Sanofi
$49.40 /

+0.59 (+1.21%)

02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
01/19/21 UBS
Sanofi price target lowered to EUR 99 from EUR 100 at UBS
SRPT Sarepta
$84.40 /

-1.39 (-1.62%)

03/02/21 RBC Capital
Sarepta price target lowered to $132 from $143 at RBC Capital
03/02/21 Piper Sandler
Sarepta price target lowered to $130 from $140 at Piper Sandler
02/26/21 Mizuho
Sarepta price target raised to $160 from $158 at Mizuho
02/25/21 Piper Sandler
Piper says Sarepta's Amondys 45 approval comes with 'relatively clean label'
SRPT Sarepta
$84.40 /

-1.39 (-1.62%)

SNY Sanofi
$49.40 /

+0.59 (+1.21%)

SLDB Solid Biosciences
$6.45 /

-3.115 (-32.58%)

REGN Regeneron
$482.31 /

-1.17 (-0.24%)

PTCT PTC Therapeutics
$57.73 /

-0.3 (-0.52%)

PKI PerkinElmer
$125.97 /

-0.715 (-0.56%)

NVS Novartis
$85.96 /

+0.66 (+0.77%)

FOLD Amicus
$10.49 /

-0.28 (-2.60%)

DYN Dyne Therapeutics
$16.62 /

-0.12 (-0.72%)

CYTK Cytokinetics
$23.85 /

-0.42 (-1.73%)

CPRX Catalyst Pharmaceuticals
$4.12 /

+0.19 (+4.83%)

BIIB Biogen
$259.78 /

-0.37 (-0.14%)

BHVN Biohaven Pharmaceutical
$75.72 /

-5.655 (-6.95%)

ALXN Alexion
$153.32 /

+1.14 (+0.75%)

  • 16
    Mar
  • 21
    Jan
  • 29
    Sep
  • 17
    Sep
  • 17
    Jul
  • 27
    May
SNY Sanofi
$49.40 /

+0.59 (+1.21%)

REGN Regeneron
$482.31 /

-1.17 (-0.24%)

NVS Novartis
$85.96 /

+0.66 (+0.77%)

FOLD Amicus
$10.49 /

-0.28 (-2.60%)

BIIB Biogen
$259.78 /

-0.37 (-0.14%)

ALXN Alexion
$153.32 /

+1.14 (+0.75%)

SRPT Sarepta
$84.40 /

-1.39 (-1.62%)

SNY Sanofi
$49.40 /

+0.59 (+1.21%)

SLDB Solid Biosciences
$6.45 /

-3.115 (-32.58%)

REGN Regeneron
$482.31 /

-1.17 (-0.24%)

PTCT PTC Therapeutics
$57.73 /

-0.3 (-0.52%)

PKI PerkinElmer
$125.97 /

-0.715 (-0.56%)

ORPH Orphazyme
$13.30 /

+0.84 (+6.74%)

NVS Novartis
$85.96 /

+0.66 (+0.77%)

FOLD Amicus
$10.49 /

-0.28 (-2.60%)

DYN Dyne Therapeutics
$16.62 /

-0.12 (-0.72%)

CYTK Cytokinetics
$23.85 /

-0.42 (-1.73%)

CPRX Catalyst Pharmaceuticals
$4.12 /

+0.19 (+4.83%)

BIIB Biogen
$259.78 /

-0.37 (-0.14%)

ALXN Alexion
$153.32 /

+1.14 (+0.75%)

REGN Regeneron
$482.31 /

-1.17 (-0.24%)

FOLD Amicus
$10.49 /

-0.28 (-2.60%)

CYTK Cytokinetics
$23.85 /

-0.42 (-1.73%)

BIIB Biogen
$259.78 /

-0.37 (-0.14%)

ALXN Alexion
$153.32 /

+1.14 (+0.75%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.